CO4960642A1 - PROTEIN INHIBITORS FARNESIL TRANSFERASAS PROTEINOFARNESIL TRANSFERASE INHIBITORS AND COMPOSITION - Google Patents

PROTEIN INHIBITORS FARNESIL TRANSFERASAS PROTEINOFARNESIL TRANSFERASE INHIBITORS AND COMPOSITION

Info

Publication number
CO4960642A1
CO4960642A1 CO97028769A CO97028769A CO4960642A1 CO 4960642 A1 CO4960642 A1 CO 4960642A1 CO 97028769 A CO97028769 A CO 97028769A CO 97028769 A CO97028769 A CO 97028769A CO 4960642 A1 CO4960642 A1 CO 4960642A1
Authority
CO
Colombia
Prior art keywords
inhibitors
transferasas
proteinofarnesil
farnesil
composition
Prior art date
Application number
CO97028769A
Other languages
Spanish (es)
Inventor
Ellen M Dobrusin
Annette Marian Doherty
James Kalterbronn
Leonard Stanley
Daniele M Mcnamara
Joseph Dennis
Leopold Sebolt
Judith Shuler
Kevon R Shuler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO4960642A1 publication Critical patent/CO4960642A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención se refiere a compuestos de ácidocarbámico y propionamida que son inhibidores de enzima proteinofarnesiltransferasa, que tienen la Fórmuladonde:R21 es hidrógeno o alquilo C1 -C6 ;RQ esn es 0 ó 1;A es -CORa , -CO2 Ra´ , -CONHRa´ , -CSRa , -C(S)ORa´ , -C(S)NHRa´, -SO2 Ra , -CONRa Ra ",Ra , Ra´ y Ra" son independientemente alquilo C1 -C6 , -(CH2 )m -cicloalquilo, -(CH2 )m -arilo o -(CH2 )m -heteroarilo;cada m es independientemente de 0 a 3;R1 , R2 y R4 son independientemente hidrógeno o alquilo C1 -C6 ;R3 es , -(CH2 )m -heteroarilo,-(CH2 )m -(CH2 )m -naftilo, -(CH2 )m -(heteroarilo sustituido con Rb ), o alquilo C1 -C6 ;t es 2 a 6; ...The present invention relates to carbamic acid and propionamide compounds which are proteinophanesyltransferase enzyme inhibitors, having the Formula where: R21 is hydrogen or C1-C6 alkyl; RQ is 0 or 1; A is -CORa, -CO2 Ra ', - CONHRa´, -CSRa, -C (S) ORa´, -C (S) NHRa´, -SO2 Ra, -CONRa Ra ", Ra, Ra´ and Ra" are independently C1-C6 alkyl, - (CH2) m -cycloalkyl, - (CH2) m -aryl or - (CH2) m -heteroaryl; each m is independently 0 to 3; R1, R2 and R4 are independently hydrogen or C1-C6 alkyl; R3 is, - (CH2) m -heteroaryl, - (CH2) m - (CH2) m -naphthyl, - (CH2) m - (heteroaryl substituted with Rb), or C1-C6 alkyl; t is 2 to 6; ...

CO97028769A 1996-05-22 1997-05-26 PROTEIN INHIBITORS FARNESIL TRANSFERASAS PROTEINOFARNESIL TRANSFERASE INHIBITORS AND COMPOSITION CO4960642A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1611096P 1996-05-22 1996-05-22
US3366296P 1996-12-17 1996-12-17

Publications (1)

Publication Number Publication Date
CO4960642A1 true CO4960642A1 (en) 2000-09-25

Family

ID=26688183

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97028769A CO4960642A1 (en) 1996-05-22 1997-05-26 PROTEIN INHIBITORS FARNESIL TRANSFERASAS PROTEINOFARNESIL TRANSFERASE INHIBITORS AND COMPOSITION

Country Status (18)

Country Link
EP (1) EP0938494A1 (en)
JP (1) JP2000511527A (en)
CN (1) CN1219174A (en)
AU (1) AU728477B2 (en)
BG (1) BG102936A (en)
BR (1) BR9709354A (en)
CA (1) CA2253934A1 (en)
CO (1) CO4960642A1 (en)
CZ (1) CZ376498A3 (en)
EA (1) EA199801031A1 (en)
EE (1) EE9800408A (en)
GE (1) GEP20012500B (en)
IL (1) IL126833A0 (en)
NO (1) NO985405L (en)
NZ (1) NZ332712A (en)
PL (1) PL330120A1 (en)
SK (1) SK161098A3 (en)
WO (1) WO1997044350A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090948A (en) * 1996-01-30 2000-07-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6028201A (en) * 1996-01-30 2000-02-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0944387A1 (en) * 1996-01-30 1999-09-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5981562A (en) * 1996-01-30 1999-11-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5968965A (en) * 1996-01-30 1999-10-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
WO1998046625A1 (en) * 1997-04-11 1998-10-22 Warner-Lambert Company Dipeptide inhibitors of protein farnesyltransferase
US6737410B1 (en) 1997-04-11 2004-05-18 Warner-Lambert Company Inhibitors of protein farnesyl transferase
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
BR9909961A (en) * 1998-04-27 2000-12-26 Warner Lambert Co Alkyl and alkenyl functionalized derivatives of glycinamides as farnesyl transferase inhibitors
US6316436B1 (en) 1998-12-08 2001-11-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2477400A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001051494A1 (en) 2000-01-12 2001-07-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2002188646A (en) * 2000-12-20 2002-07-05 Nsk Ltd Rolling bearing and bearing device
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
WO2005049589A2 (en) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
DE102004015723A1 (en) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
CN101679266B (en) 2007-03-01 2015-05-06 诺华股份有限公司 PIM kinase inhibitors and methods of their use
BRPI0812159A2 (en) 2007-05-21 2017-05-02 Novartis Ag csf-1r inhibitors, compositions and methods of use
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibitors of akt activity
JP6073677B2 (en) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Fused heterocyclic compounds and their use
BR112012008849A2 (en) 2009-10-14 2015-09-22 Schering Corp compound, pharmaceutical composition, and use of a compound
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
BR112012023021A2 (en) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc indazole compounds and their uses
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (en) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． RNA interference-mediated inhibition of catenin (cadherin-binding protein) β1 (CTNNB1) gene expression using small interfering nucleic acids (siNA)
HUE044815T2 (en) 2010-08-17 2019-11-28 Sirna Therapeutics Inc RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
BR112015012295A8 (en) 2012-11-28 2023-03-14 Merck Sharp & Dohme USE OF A WEE1 INHIBITOR, E, KIT TO IDENTIFY A PATIENT WITH CANCER
BR112015013611A2 (en) 2012-12-20 2017-11-14 Merck Sharp & Dohme compound and pharmaceutical composition
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
JP6491202B2 (en) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Polycyclic inhibitors of cyclin dependent kinase 7 (CDK 7)
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016160617A2 (en) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
JP7160833B2 (en) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． anti-SIRP alpha antibody
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
EP0725650A4 (en) * 1993-09-30 1999-02-03 Merck & Co Inc Inhibitors of farnesyl-protein transferase
KR100362338B1 (en) * 1993-11-05 2003-04-08 워너-램버트 캄파니 Protein: Substituted Di- and Tripeptide Inhibitors of Farnesyl Transferase
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase

Also Published As

Publication number Publication date
SK161098A3 (en) 2000-06-12
AU728477B2 (en) 2001-01-11
CN1219174A (en) 1999-06-09
CZ376498A3 (en) 1999-02-17
GEP20012500B (en) 2001-07-25
PL330120A1 (en) 1999-04-26
EP0938494A1 (en) 1999-09-01
NO985405L (en) 1999-01-19
CA2253934A1 (en) 1997-11-27
JP2000511527A (en) 2000-09-05
EA199801031A1 (en) 1999-06-24
NO985405D0 (en) 1998-11-20
EE9800408A (en) 1999-06-15
BR9709354A (en) 1999-08-10
IL126833A0 (en) 1999-08-17
WO1997044350A1 (en) 1997-11-27
AU2805897A (en) 1997-12-09
NZ332712A (en) 2000-07-28
BG102936A (en) 1999-09-30

Similar Documents

Publication Publication Date Title
CO4960642A1 (en) PROTEIN INHIBITORS FARNESIL TRANSFERASAS PROTEINOFARNESIL TRANSFERASE INHIBITORS AND COMPOSITION
CO5150173A1 (en) COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
DK0725788T3 (en) 2'-amido and 2'-peptide modified oligonucleotides
BR9909325A (en) Compositions of non-elastomeric polyurethane
ATE249466T1 (en) CHAIN EXTENDER CONTAINING SILICON
DK0659174T3 (en) Derivatives of valproic acid and 2-valproic acid amides as well as their use as anticonvulsants
ATE159945T1 (en) BETA-AMINOALKYL AND BETA-N-PEPTIDYLAMINOALKYLBORIC ACID
ES2128535T3 (en) NUCLEOSIDES AND OLIGONUCLEOTIDES WITH 2'-ETER GROUPS.
DK1075258T3 (en) New fatty acid analogues for the treatment of obesity
PT982398E (en) NUCLEIC ACIDS AND THEIR USES IN THE BETA-LACTAMASE TEST
BR9915679A (en) Compositions and methods to increase bone mineralization
TR199901674T2 (en)
DE69615682D1 (en) N- (1-ALKYL-5-PHENYL-2,3,4,5-TETRAHYDRO-1-H-BENZO [B] [1,5] -DIAZEPIN-3-YL) -ACETAMIDE
ATE69239T1 (en) OLIGOPEPTIDYLNITRILE DERIVATIVES, AGENTS CONTAINING THEM, PROCESSES FOR THEIR PREPARATION AND THEIR USE.
FR2699403B1 (en) Compositions for conditioning keratin materials based on alkylpolyglycosides and their use for washing and conditioning the hair.
BR9804309A (en) Surfactants
DE60214704D1 (en) POLYSILOXANE AND OTHER POLYMERS CONTAINING COMPOSITIONS
ATE250594T1 (en) DIHYDROBENZOFURANES AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS
DE69815380D1 (en) N, N'-BIS (SULFONYL) HYDRAZINE WHICH ARE USEFUL AS ANTINEOPLASTIC AGENTS
BR9812782A (en) "o-substituted n, n-diacyl-hydroxylamine bleach activators and compositions employing the same"
TW342416B (en) Treating agent for synthetic fiber
ATE224398T1 (en) PHOSPHORIC ACID ESTERS
BR9900817A (en) Asymmetric siloxide compounds.
BR9815004A (en) Stabilized fabric softening compositions.
WO2002042262A3 (en) Alkylthio- and aryl(heteroyl)thio-substituted p-phenylenediamines, their manufacture and their use in rubber